Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Authors' reply: Communicating evidence-based practice in menopause

We appreciate the concerns raised by Dr Prior in her correspondence on our Primer (Menopause. Nat. Rev. Dis. Primers 1, 15004 (2015))1, which raised some interesting points (Perimenopause and menopause as oestrogen deficiency while ignoring progesterone. Nat. Rev. Dis. Primers (2015))2.

The selection of menopause as a topic in this journal highlights the importance of this life phase for women. We were required to format our article according to specific journal guidelines, but this should not to be interpreted as ‘medicalizing menopause’. Rather, our enthusiasm to communicate evidence-based practice to the readership counterbalanced the concern about casting menopause as a disease state. It is difficult to compose a review that encompasses such a large part of a woman's life and that addresses the short-term and chronic conditions arising from menopause, while highlighting the nuances between the menopausal transition and the postmenopausal years.

We note the contribution that Dr Prior has made to the literature regarding treatment of vasomotor symptoms with progesterone3. However, we do not agree that oestrogen has never been shown to reduce vasomotor symptoms in perimenopausal women. First, the many trials of oestrogen treatment of hot flushes have adhered to the US FDA guidance4, which recommends that ‘only postmenopausal women be included’. However, the inclusion criterion of 6 months of amenorrhoea accompanied by follicle-stimulating hormone levels of >40 mIU per ml almost certainly includes women who are perimenopausal. Second, studies on hormonal control of hot flushes in perimenopausal women that have used oestrogen in combination with progestin have demonstrated efficacy against hot flushes specifically in perimenopausal women5,6. Low-dose transdermal oestradiol has also been shown to be effective in combination with a levonorgestrel intrauterine system in controlling hot flushes in perimenopausal women7,8.

Finally, we do not agree with Dr Prior that the concept of oestrogen deficiency is ‘out of date’. It may not be perfect, but it is the best explanation we currently have.


  1. 1

    Davis, S. R. et al. Menopause. Nat. Rev. Dis. Primers 1, 15004 (2015).

    Article  Google Scholar 

  2. 2

    Prior, J. C. Perimenopause and menopause as oestrogen deficiency while ignoring progesterone. Nat. Rev. Dis. Primers (2015).

  3. 3

    Hitchcock, C. L. & Prior, J. C. Oral micronized progesterone for vasomotor symptoms — a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 19, 886–893 (2012).

    Article  Google Scholar 

  4. 4

    U.S. Department of Health and Human Services. Guidance for Industry. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms — recommendations for clinical evaluation. FDA[online], (2003).

  5. 5

    Shargil, A. A. Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three-year prospective study. Int. J. Fertil. 30, 15–28 (1985).

    CAS  PubMed  Google Scholar 

  6. 6

    Casper, R. F., Dodin, S. & Reid, R. The effect of 20 mcg ethinyl estradiol/1 gm norethindrone acetate (Minestrin), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic periomenopausal women. Menopause 4, 139–147 (1997).

    Article  Google Scholar 

  7. 7

    Santoro, N. et al. Use of a levonorgestrel-containing IUS with supplemental estrogen improves symptoms in perimenoapusal women — a pilot study. Menopause (in the press).

  8. 8

    Hampton, N. R. et al. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum. Reprod. 20, 2653–2660 (2005).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Susan R. Davis.

Ethics declarations

Competing interests

S.R.D. has received honoraria from Abbott Pharmaceuticals and is an investigator for Trimel Pharmaceuticals and Lawley Pharmaceuticals; all other authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Davis, S., Santoro, N., Lambrinoudaki, I. et al. Authors' reply: Communicating evidence-based practice in menopause. Nat Rev Dis Primers 1, 15032 (2015).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing